PFE - ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor

ESSA Pharma Inc. (NASDAQ:EPIX) [TSX-V: EPI] is a Canadian/U.S. clinical-stage pharmaceutical company which recently began Phase 1 clinical trials for its lead drug EPI-7386, a novel treatment for men with castration-resistant prostate cancer ("CRPC") where the cancer is progressing despite the men having been treated with current standard of care therapies.

As described in more detail below, EPI-7386 prevents androgen receptor (“AR”) activation by selectively binding to the N-terminal domain ("NTD") of the AR which results in the disruption of the primary pathway that drives prostate cancer growth.

According to ESSA's recent webcast